search
Back to results

A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension

Primary Purpose

Hypotension, Orthostatic

Status
Terminated
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
midodrine hydrochloride (ProAmatine®)
Sponsored by
Shire
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypotension, Orthostatic focused on measuring Neurology, Cardiology

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The male or female subjects must be 18 years of age or older and ambulatory. (Subjects must not require assistance with a walker or wheelchair to perform regular daily activities at all times.) Women of childbearing potential must have a negative serum beta HCG pregnancy test at screening and baseline. The subject has been diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathy (i.e. neurogenic orthostatic hypotension). The subject manifests one of the following symptoms while standing or has a history of one of the following when not treated for orthostatic hypotension: dizziness, lightheadedness, feeling faint or feeling like they may black out. The subject is willing and able to undergo the procedures required by this protocol including morning office visits, assessment completion, protocol compliance and participation in the wash-out period. The subject has signed an Institutional-Review-Board approved written informed consent form prior to any study procedures taking place. Exclusion Criteria: The subject is a pregnant or lactating female. The subject has pre-existing sustained supine hypertension greater than 180 mm Hg systolic and 110 mm Hg diastolic. The subject is taking medications such as vasodilators, pressors, diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, combined alpha and beta-blockers, MAOI's, herbals or specific mixed effect medications. The Principal Investigator deems any laboratory test abnormality clinical significant. The subject has a diagnosis of any of the following disorders at the time of screening: pheochromocytoma; cardiac conditions including: congestive heart failure within the previous 6 months, myocardial infarction within the previous 6 months, symptomatic coronary artery disease, history of ventricular tachycardia, or uncontrolled cardiac arrhythmias; thyrotoxicosis; uncontrolled diabetes mellitus (uncontrolled defined as a HgbA1c greater than or equal to 10%); history of cerebrovascular accident, transient ischemic attack (TIA) or symptomatic carotid artery stenosis within the previous 6 months; history of coagulopathies; pulmonary hypertension; severe psychiatric disorders; renal failure (Creatinine equal to or greater than 2 times the upper limit of normal) The subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of the tests and/or measurements administered in this trial, or that might increase the risk to the subject.

Sites / Locations

  • Suncoast Neuroscience Associates, Inc.
  • Neurological Associates of Delaware Valley
  • Diabetes & Glandular Disease Research Associates, PA,

Outcomes

Primary Outcome Measures

Average Standing Time
Standing time was assessed after the participant and clinician questionnaires and blood pressure measurements are completed.
Average Standing Time
Standing time was assessed after the participant and clinician questionnaires and blood pressure measurements are completed.

Secondary Outcome Measures

Full Information

First Posted
September 20, 2002
Last Updated
June 24, 2021
Sponsor
Shire
search

1. Study Identification

Unique Protocol Identification Number
NCT00046163
Brief Title
A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension
Official Title
A Phase IV, Multi-Center, Double-Blind, Parallel Group, Randomized, Placebo-Controlled Study to Assess the Clinical Benefit of Three Doses of Midodrine Hydrochloride (ProAmatine®) in Subjects With Neurogenic Orthostatic Hypotension
Study Type
Interventional

2. Study Status

Record Verification Date
June 2021
Overall Recruitment Status
Terminated
Why Stopped
Study was terminated due to poor enrollment
Study Start Date
September 5, 2002 (Actual)
Primary Completion Date
August 6, 2003 (Actual)
Study Completion Date
August 6, 2003 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shire

4. Oversight

5. Study Description

Brief Summary
We are seeking male and female patients to voluntarily take part in a clinical research study. Patients must be aged 18 or older and diagnosed with symptomatic orthostatic hypotension (low blood pressure while in the upright position) due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathies (i.e. neurogenic orthostatic hypotension). Symptoms of low blood pressure include dizziness, lightheadedness, changes in vision and generalized weakness upon standing. The main effect of the drug being studied is to increase blood pressure in the upright position so symptoms will decrease. The purpose of this clinical study is to further assess the clinical effect of high dose midodrine hydrochloride (ProAmatine®), an approved treatment for orthostatic hypotension. During the course of the study, participants will receive either ProAmatine® or a placebo. Assessments will be made using questionnaires that measure symptom and activity levels. Blood pressure in the lying down, sitting and standing positions will be measured. Patients will also complete standing time assessments. They will be asked to remain standing without moving until they feel sufficiently lightheaded, or dizzy, or feel faint so that they would feel more comfortable sitting down.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypotension, Orthostatic
Keywords
Neurology, Cardiology

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
150 (false)

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
midodrine hydrochloride (ProAmatine®)
Primary Outcome Measure Information:
Title
Average Standing Time
Description
Standing time was assessed after the participant and clinician questionnaires and blood pressure measurements are completed.
Time Frame
Visit 6, 1 hour post-dose
Title
Average Standing Time
Description
Standing time was assessed after the participant and clinician questionnaires and blood pressure measurements are completed.
Time Frame
Visit 7, 1 hour post-dose

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The male or female subjects must be 18 years of age or older and ambulatory. (Subjects must not require assistance with a walker or wheelchair to perform regular daily activities at all times.) Women of childbearing potential must have a negative serum beta HCG pregnancy test at screening and baseline. The subject has been diagnosed with symptomatic orthostatic hypotension due to Parkinson's disease, multiple system atrophy, pure autonomic failure or autonomic neuropathy (i.e. neurogenic orthostatic hypotension). The subject manifests one of the following symptoms while standing or has a history of one of the following when not treated for orthostatic hypotension: dizziness, lightheadedness, feeling faint or feeling like they may black out. The subject is willing and able to undergo the procedures required by this protocol including morning office visits, assessment completion, protocol compliance and participation in the wash-out period. The subject has signed an Institutional-Review-Board approved written informed consent form prior to any study procedures taking place. Exclusion Criteria: The subject is a pregnant or lactating female. The subject has pre-existing sustained supine hypertension greater than 180 mm Hg systolic and 110 mm Hg diastolic. The subject is taking medications such as vasodilators, pressors, diuretics, ACE inhibitors, angiotensin receptor blockers, beta-blockers, combined alpha and beta-blockers, MAOI's, herbals or specific mixed effect medications. The Principal Investigator deems any laboratory test abnormality clinical significant. The subject has a diagnosis of any of the following disorders at the time of screening: pheochromocytoma; cardiac conditions including: congestive heart failure within the previous 6 months, myocardial infarction within the previous 6 months, symptomatic coronary artery disease, history of ventricular tachycardia, or uncontrolled cardiac arrhythmias; thyrotoxicosis; uncontrolled diabetes mellitus (uncontrolled defined as a HgbA1c greater than or equal to 10%); history of cerebrovascular accident, transient ischemic attack (TIA) or symptomatic carotid artery stenosis within the previous 6 months; history of coagulopathies; pulmonary hypertension; severe psychiatric disorders; renal failure (Creatinine equal to or greater than 2 times the upper limit of normal) The subject has a concurrent chronic or acute illness, disability, or other condition that might confound the results of the tests and/or measurements administered in this trial, or that might increase the risk to the subject.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Study Director
Organizational Affiliation
Takeda
Official's Role
Study Director
Facility Information:
Facility Name
Suncoast Neuroscience Associates, Inc.
City
Saint Petersburg
State/Province
Florida
Country
United States
Facility Name
Neurological Associates of Delaware Valley
City
Upland
State/Province
Pennsylvania
Country
United States
Facility Name
Diabetes & Glandular Disease Research Associates, PA,
City
San Antonio
State/Province
Texas
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.ndrf.org
Description
The National Dysautonomia Research Foundation
URL
http://www.centerwatch.com
Description
CenterWatch - Clinical Trials Resource Site

Learn more about this trial

A Phase IV Study in Subjects With Neurogenic Orthostatic Hypotension

We'll reach out to this number within 24 hrs